Studies whether early, intensive cholesterol lowering can shrink artery plaque in young adults
Studies adults with familial hypercholesterolemia under age 50 receiving early, intensive cholesterol-lowering treatment.
Key facts
- Who runs it
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- Plaque Reversal With Early, Aggressive Lipid Lowering Therapy
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 7 Jul 2022
- Expected to end
- Apr 2027
- Type of study
- Observational
- Record updated
- 2 October 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 50 with heterozygous familial hypercholesterolemia and LDL cholesterol above 100 mg/dl (2.6 mmol/L). It tests whether early, intensive cholesterol-lowering treatment shrinks plaque in the arteries.
- Age
- 18 to 50 years
- Sex
- Men and women can join.
- Disease stage
- Heterozygous familial hypercholesterolemia (an inherited condition with high cholesterol). No earlier heart or artery events.
- Biomarker or test result
- LDL cholesterol above 100 mg/dl (>2.6 mmol/L) at the start of the trial.
Main reasons for not taking part
- Kidney problems (eGFR below 30 ml/min)
- Earlier heart or artery disease events caused by atherosclerosis
- Atrial fibrillation
- Another treatment or condition that could disturb the trial, in the investigator's opinion
- Unable or unwilling to follow the trial rules
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Diagnosed with heterozygous familial hypercholesterolemia
- Adult between 18 and 50 years old
- LDL cholesterol levels above 100 mg/dl (>2.6 mmol/L) at inclusion
Who cannot take part
- History of atherosclerotic cardiovascular events
- Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
- Renal insufficiency, defined as eGFR < 30 ml/min
- Atrial fibrillation
- Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Where in Netherlands
- Amsterdam UMC, location AMCAmsterdam, NetherlandsContact: Erik S. G. Stroes, MD, PhDTaking people
About the trial
What the trial wants to find out
This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Plaque Reversal With Early, Aggressive Lipid Lowering Therapy
- Plain-language title
- Studies whether early, intensive cholesterol lowering can shrink artery plaque in young adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05783804, who can take part
- Record updated
- 2 October 2025